ADVERTISEMENT
ADVERTISEMENT

Major pharmaceutical companies are diving into the gene therapy pool

therapy pool Here are a few of the recent deals: The Giant The Gene Therapy Co. The Deal Biogen Inc. Genovo Inc. Seed money: $38 million, 5 years Bristol-Myers Somatix Therapy Corp. Initial $10 million Squibb Co. stock purchase Ciba-Geigy Chiron Corp. 49.9% stake for Ltd. $2.1 billion Glaxo Sequana Therapeutics Undisclosed Wellcome Inc. Megabios Corp. milestone Spectra Biomedical Inc. payments Merck & Co. Vical Inc. $10.4 million Inc. invested to date Rh’ne-Poulenc 14 gene therapy firms

The Scientist Staff

therapy pool Here are a few of the recent deals:

 The Giant The Gene Therapy Co. The Deal Biogen Inc. Genovo Inc. Seed money: $38 million, 5 years Bristol-Myers Somatix Therapy Corp. Initial $10 million Squibb Co. stock purchase Ciba-Geigy Chiron Corp. 49.9% stake for Ltd. $2.1 billion Glaxo Sequana Therapeutics Undisclosed Wellcome Inc. Megabios Corp. milestone Spectra Biomedical Inc. payments Merck & Co. Vical Inc. $10.4 million Inc. invested to date Rh’ne-Poulenc 14 gene therapy firms $400 million for Rorer partner network Sandoz Ltd. Genetic Therapy Inc. $295 million purchase 
[home] [top] [search] [previous] [next]
(The Scientist, Vol:9, #22, pg.10 , November 13, 1995)
(Copyright © The Scientist, Inc.)

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT